- Home
- UWMC vs AKBA Comparison
UWMC vs AKBA Comparison
Compare UWMC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- AKBA
- Stock Information
- Founded
- UWMC 1986
- AKBA 2007
- Country
- UWMC United States
- AKBA United States
- Employees
- UWMC N/A
- AKBA N/A
- Industry
- UWMC Finance: Consumer Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- AKBA Health Care
- Exchange
- UWMC Nasdaq
- AKBA Nasdaq
- Market Cap
- UWMC 876.2M
- AKBA 861.7M
- IPO Year
- UWMC N/A
- AKBA 2014
- Fundamental
- Price
- UWMC $5.82
- AKBA $3.19
- Analyst Decision
- UWMC Hold
- AKBA Strong Buy
- Analyst Count
- UWMC 7
- AKBA 5
- Target Price
- UWMC $5.54
- AKBA $6.90
- AVG Volume (30 Days)
- UWMC 10.2M
- AKBA 3.9M
- Earning Date
- UWMC 08-07-2025
- AKBA 08-07-2025
- Dividend Yield
- UWMC 6.87%
- AKBA N/A
- EPS Growth
- UWMC 112.84
- AKBA N/A
- EPS
- UWMC 0.07
- AKBA N/A
- Revenue
- UWMC $2,622,828,000.00
- AKBA $203,733,000.00
- Revenue This Year
- UWMC $16.65
- AKBA $27.95
- Revenue Next Year
- UWMC $16.18
- AKBA $43.88
- P/E Ratio
- UWMC $87.80
- AKBA N/A
- Revenue Growth
- UWMC 13.45
- AKBA 16.75
- 52 Week Low
- UWMC $3.80
- AKBA $1.24
- 52 Week High
- UWMC $9.74
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- UWMC 72.08
- AKBA 41.27
- Support Level
- UWMC $5.27
- AKBA $3.02
- Resistance Level
- UWMC $5.68
- AKBA $3.44
- Average True Range (ATR)
- UWMC 0.30
- AKBA 0.16
- MACD
- UWMC 0.09
- AKBA -0.03
- Stochastic Oscillator
- UWMC 95.56
- AKBA 31.03
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.